InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
Current research into the potential therapeutic effects of cannabinol (CBN)
How do cannabinoids interact with the human body? There has been a significant growth in interest and research into the potential therapeutic properties of cannabinoids.
April 8, 2021
